Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 3:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 234 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Itraconazole Clear all
Terminated Phase 1 Interventional

Drug-Drug Interaction and Safety of AZD4041 Study (Part 1) and Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AZD4041 Study in Opioid Use Disorder (Part 2).

NCT06406400
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
AZD4041, Itraconazole, Buprenorphine, Buprenorphine / Naloxone, Hydromorphone, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 26, 2025 · Synced Oct 20, 2026, 3:53 AM EDT
Not listed Early Phase 1 Interventional

Evaluating the Healing of Diabetic Foot Ulcers With Compounded Anti-Infective Irrigation Therapy

NCT05076955
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
vancomycin-tobramycin-itraconazole
Drug
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Oct 13, 2021 · Synced Oct 20, 2026, 3:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PK Study to Assess Drug-drug Interaction Between Sitravatinib and a P-gp Inducer and an Inhibitor.

NCT05255276
View directory record Official record
Conditions
Healthy Adults
Interventions
Sitravatinib 50 mg, Sitravatinib 100 mg, Itraconazole, Rifampin
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2024 · Synced Oct 20, 2026, 3:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Open-Label, Single-Dose Study to Evaluate the Safety and PK of DIC075V in Subjects With Renal Insufficiency and Hepatic Impairment Compared to Healthy Subjects and Evaluate the Safety and Pharmacokinetics of HPβCD When Administered in DIC075V Compared to Sporanox® in Healthy Subjects

NCT00805090
View directory record Official record
Conditions
Renal Insufficiency, Chronic, Hepatic Insufficiency, Healthy
Interventions
Sporanox, Diclofenac Sodium
Drug
Lead sponsor
Javelin Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
3
States / cities
Orlando, Florida • Minneapolis, Minnesota • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 30, 2009 · Synced Oct 20, 2026, 3:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect Of Itraconazole On The Pharmacokinetics Of Palbociclib

NCT02131298
View directory record Official record
Conditions
Healthy
Interventions
Palbociclib Alone, Palbociclib plus itraconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 30, 2014 · Synced Oct 20, 2026, 3:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A 2-Part Study to Assess Potential Metabolism-Based Drug-Drug Interactions of E2006 When Coadministered With Itraconazole, Rifampin, Midazolam, or Bupropion

NCT02085967
View directory record Official record
Conditions
Healthy Subjects
Interventions
rifampin 600 mg, itraconazole 200 mg, midazolam 2 mg with bupropion 75 mg, E2006
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
106 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 3, 2015 · Synced Oct 20, 2026, 3:53 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Phase Ib/II Study Evaluating Orteronel (Without Prednisone) Combined With Itraconazole In Men With Castration-Resistant Prostate Cancer (CRPC)

NCT02054793
View directory record Official record
Conditions
Prostate Cancer, Castration-resistant Prostate Cancer
Interventions
Itraconazole, Orteronel
Drug
Lead sponsor
Emmanuel Antonarakis, MD
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 23, 2014 · Synced Oct 20, 2026, 3:53 AM EDT
Completed Early Phase 1 Interventional Results available

Neoadjuvant Itraconazole in Non-small Cell Lung Cancer

NCT02357836
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Itraconazole
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 3, 2021 · Synced Oct 20, 2026, 3:53 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

NCT07070232
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
BNT326, Pumitamig, Itraconazole, Paroxetine
Drug
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
1,438 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
19
States / cities
Phoenix, Arizona • San Francisco, California • Hartford, Connecticut + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 20, 2026, 3:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Food-effect, Drug-Drug Interaction (DDI), and Formulation Bridging Study

NCT03555617
View directory record Official record
Conditions
Inflammatory Bowel Disease
Interventions
TD-1473, Itraconazole
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
19 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 14, 2021 · Synced Oct 20, 2026, 3:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Effects of Itraconazole and Rifampin on Selpercatinib (LY3527723) in Healthy Participants

NCT05338489
View directory record Official record
Conditions
Healthy
Interventions
Selpercatinib, Itraconazole, Rifampin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 19, 2025 · Synced Oct 20, 2026, 3:53 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)

NCT05384626
View directory record Official record
Conditions
Locally Advanced Solid Tumor, Metastatic Solid Tumor
Interventions
Neladalkib (NVL-655), Midazolam, Repaglinide, Itraconazole
Drug
Lead sponsor
Nuvalent Inc.
Industry
Eligibility
12 Years and older
Enrollment
840 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
21
States / cities
Orange, California • Sacramento, California • Stanford, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 20, 2026, 3:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Amount of Drug That Becomes Available in the Blood Circulation When Savolitinib is Administered Alone and in Combination With Itraconazole

NCT04121910
View directory record Official record
Conditions
Solid Tumour
Interventions
Savolitinib, Itraconazole
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jan 23, 2020 · Synced Oct 20, 2026, 3:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Multiple Doses of Itraconazole, Phenytoin, and Paroxetine on the Single-Dose Pharmacokinetics of Poziotinib in Healthy Adult Participants

NCT04981704
View directory record Official record
Conditions
Healthy
Interventions
Poziotinib, Itraconazole, Phenytoin, Paroxetine
Drug
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 5, 2021 · Synced Oct 20, 2026, 3:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-drug Interaction Study of Clemizole (EPX-100) in Healthy Participants

NCT07824193
View directory record Official record
Conditions
Drug Drug Interaction
Interventions
EPX-100, Itraconazole, Phenytoin, Omeprazole, Midazolam, Bupropion
Drug
Lead sponsor
Epygenix
Industry
Eligibility
18 Years to 55 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 20, 2026, 3:53 AM EDT
Completed Phase 2 Interventional

A Study of Itraconazole in the Treatment and Prevention of Histoplasmosis, a Fungal Infection, in Patients With AIDS

NCT00000975
View directory record Official record
Conditions
HIV Infections, Histoplasmosis
Interventions
Itraconazole
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1994
U.S. locations
12
States / cities
Los Angeles, California • Chicago, Illinois • Indianapolis, Indiana + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 20, 2026, 3:53 AM EDT
Recruiting Phase 1 Interventional

A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

NCT03460977
View directory record Official record
Conditions
Metastatic Castration Resistant Prostate Cancer (mCRPC), Small Cell Lung Cancer (SCLC), Follicular Lymphoma (FL)
Interventions
Mevrometostat (PF-06821497), Enzalutamide, Itraconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
453 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
45
States / cities
Tucson, Arizona • Anaheim, California • Duarte, California + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 20, 2026, 3:53 AM EDT
Recruiting Phase 2 Interventional

Itraconazole in Combination With Ablation for the Prevention of Esophageal Cancer in Patients With High-risk Barrett's Esophagus

NCT06732388
View directory record Official record
Conditions
Barrett Esophagus, Clinical Stage I Esophageal Adenocarcinoma AJCC v8, Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8, Esophageal Adenocarcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Endoscopic Procedure, Itraconazole, Placebo Administration, Questionnaire Administration, Radiofrequency Ablation
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
6
States / cities
Kansas City, Kansas • Ann Arbor, Michigan • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 20, 2026, 3:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Effect of Itraconazole, Rifampin, and Acid-Reducing Agents on INCB161734 Pharmacokinetics When Administered Orally in Healthy Participants

NCT07018635
View directory record Official record
Conditions
Healthy Participants
Interventions
INCB161734, Itraconazole, Rifampin, Esomeprazole, Famotidine
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 55 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 26, 2025 · Synced Oct 20, 2026, 3:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Drug Interaction Between MYK-224 and Itraconazole and Verapamil in Healthy Participants

NCT05304533
View directory record Official record
Conditions
Healthy Participants
Interventions
MYK-224, Itraconazole, Verapamil
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 13, 2023 · Synced Oct 20, 2026, 3:53 AM EDT
Completed Not applicable Interventional

A Study of Itraconazole in the Prevention of Histoplasmosis, a Fungal Infection, in HIV-Infected Patients

NCT00002438
View directory record Official record
Conditions
HIV Infections, Histoplasmosis
Interventions
Itraconazole
Drug
Lead sponsor
Janssen, LP
Industry
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
7
States / cities
Indianapolis, Indiana • Kansas City, Missouri • Memphis, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 20, 2026, 3:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY3323795 in Healthy Participants

NCT02989389
View directory record Official record
Conditions
Healthy
Interventions
LY3323795, Itraconazole, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
20 Years and older
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Apr 20, 2020 · Synced Oct 20, 2026, 3:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Effect of Multiple Doses of Itraconazole and Rifampin on the Single-Dose Pharmacokinetics of Mitapivat Sulfate (AG-348) in Healthy Adult Participants

NCT03991312
View directory record Official record
Conditions
Healthy Volunteers
Interventions
itraconazole, rifampin, mitapivat sulfate
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 23, 2019 · Synced Oct 20, 2026, 3:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Clinical Trial to Evaluate MK-4208/TERN-701 in Healthy Adult Participants (MK-4208-001/TERN701-1014)

NCT07838987
View directory record Official record
Conditions
Healthy
Interventions
TERN-701, Rabeprazole, Midazolam, Digoxin, Pravastatin, Montelukast, Omeprazole, Itraconazole, Warfarin, Rosuvastatin, Bosentan, Quinidine
Drug
Lead sponsor
Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 65 Years
Enrollment
196 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Millcreek, Utah
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 20, 2026, 3:53 AM EDT